Actavis expands manufacturing site in Iceland
Production at Actavis Hafnarfjordur site, Iceland
Actavis has announced plans to expand its manufacturing site in Iceland, increasing capacity at the site by 50%. Fifty new jobs will be created as a result.
The Hafnarfjordur, Iceland manufacturing site exports 95% of its products. After expansion the SOD-site‘s capacity will be about 1.5 billion tablets pr. year, depending on the mix of products. Production is expected to start at the new facility by year end 2010, with no disruption to current manufacturing capabilities.
The site produces many of Actavis‘ latest generics and specialises in new product launches. Actavis hf in Iceland currently employs about 300 people, mostly in production and quality. By the end of this year, 50 new jobs will be created following the expansion. Actavis Group employs over 10,000 people in 40 countries, including about 570 in Iceland.
The Hafnarfjordur site is ISO 14001 and OHSAS 18001 certified and runs on sustainable energy; electricity from hydropower and geothermal heating. Actavis remains committed to its environmental, health and safety performance, with 11 of its manufacturing sites ISO 14001 certified, seven with an OHSAS 18001 certification.
Most read news
Other news from the department manufacturing

Get the life science industry in your inbox
By submitting this form you agree that LUMITOS AG will send you the newsletter(s) selected above by email. Your data will not be passed on to third parties. Your data will be stored and processed in accordance with our data protection regulations. LUMITOS may contact you by email for the purpose of advertising or market and opinion surveys. You can revoke your consent at any time without giving reasons to LUMITOS AG, Ernst-Augustin-Str. 2, 12489 Berlin, Germany or by e-mail at revoke@lumitos.com with effect for the future. In addition, each email contains a link to unsubscribe from the corresponding newsletter.
Most read news
More news from our other portals
Last viewed contents
New mechanism of pancreatic cancer discovered
Unconventional natural gas wells associated with migraine, fatigue
Pieris Initiates Phase I Clinical Trial for Lead Anticalin Compound - Anti-VEGF PRS-050 is first Anticalin tested in humans
New combination therapy looks promising against ulcer bacteria
European Medicines Agency advises on compassionate use of daclatasvir - Opinion concerns use in combination with sofosbuvir in patients with chronic hepatitis C in urgent need of therapy to prevent progression of liver disease
Novartis completes shipment of US supply of Fluvirin seasonal influenza vaccine
A Change of Culture for Healthcare
Medicyte GmbH Benefits From Multi-Million Euro EU Grant VascuBone
Pneumonoultramicroscopicsilicovolcanoconiosis

Biofilms - an invisible threat to food safety - Hotspots for biofilms

Snake venom treatment investigated as antibiotic alternative for eye infections
